The potential of the medicinal and nutraceutical cannabis industry is clearly evidenced in the rapid growth and scale achieved by businesses in Canada and Europe. Globally, the medicinal cannabis industry is forecast to be worth USD $150 billion by 2025 (Grand View Research, 2018).
Medical Kiwi, an early-stage medicinal research and nutraceutical wellbeing company, is in a unique position as one of a handful of New Zealand companies poised to create value and carve out a significant share of this emerging and exciting growth industry.
Against the backdrop of a global health and wellness consumer mega-trend, and with sentiment towards alternative medicines and medicinal cannabis in particular rapidly evolving, the time is now to participate in the opportunity that Medical Kiwi represents.
Medical Kiwi was established to realise the global opportunities for New Zealand produced and branded, high quality, safe, effective and affordable medicinal and wellbeing cannabis products to effect real change in people’s lives and health outcomes and to create returns for stakeholders.
Significant changes in New Zealand’s legislation in 2018 have paved the way for the creation of a fully commercialised medical and nutraceutical cannabis industry. Medical Kiwi is in a unique position as one of a handful of New Zealand companies poised to create value and carve out a significant share of this emerging and exciting growth industry.
To date Medical Kiwi has:
- Successfully raise our initial seed fund capital of NZD $1 million
- Put together a strong Board of Directors with vast knowledge and expertise
- Secured a greenfield site and complete the design-build plans for our state-of-the-art facility
- Developed a clear strategy for research, manufacturing, product, marketing, sales and distribution
- Secured a cultivation licence from the Ministry of Health and apply for additional licences.
Development of the state-of-the-art facility is expected to commence late 2020 with full capacity to be reached in four years. When in full production, estimated to be early 2024, the 8,000 – 10,000m2 facility is designed to produce 30,000 – 35,000 tonne of dried product per annum, valued today at between NZD $100 – $110 million.
Medical Kiwi has been developing international supply networks and is anticipating white-labelled imported products to come on line in early-2020 and show sales revenue from mid-2020, aligning with the business’ sales, product and distribution strategy and timeline.
This puts Medical Kiwi in the premier position to realise the global opportunities for a New Zealand produced and branded high quality, safe, effective and affordable medicinal and nutraceutical product to effect real change in people’s lives and health outcomes.
If you are interested in investing in Medical Kiwi please register interest below.